Skip to content
Screener

Haemonetics HAE Plasma — Total net revenues

Other product segments

Blood Management Technologies
$88.12M
Interventional Technologies
$59.94M

Similar metrics at other companies

Coupang logo
CPNGNet other revenue — Total net revenues
$2.03B+11.4%
Evolus logo
EOLSProduct revenue, net — Total net revenues
$83.35M+21.3%
Coupang logo
CPNGOther revenue — Total net revenues
$261M+1.2%
Evolus logo
EOLSService revenue — Total net revenues
$734K+6.7%
Evolus logo
EOLSEvolysse — Total net revenues
$8.89M-8.6%
Evolus logo
EOLSJeuveau — Total net revenues
$74.46M+26.3%

Other financials

Income statement

See full
Revenue$339.4M+5.6%
Gross profit$202.8M+5.5%
Operating income$57.5M+6.7%
Net income$33.0M-3.0%
EPS (diluted)$0.72+2.9%

Balance sheet

See full
Cash & equivalents$223.4M-23.7%
Total debt$1.2B-4.1%
Total equity$837.1M-5.1%
Total assets$2.4B-3.9%

Cash flow

See full
Operating cash flow$52.3M+201%
CapEx$7.9M+111%
Free cash flow$44.4M+226%

Valuation

See full
Market cap$3.87B+6.3%
Enterprise value$4.82B+5.4%
P/E25.7×-10.5×
P/S2.9×+0.2×

Profitability

See full
Gross margin59%+2.1pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin21.5%+7.5pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.4×0.0×
Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:09 AM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000313143-26-000120
Line itemThree Months Ended / June 27, 2026June 28, 2025
Apheresis
Plasma$155,524$145,074
Other35,79436,662
Apheresis net revenues$191,318$181,736
MedSurg
Interventional Technologies$59,942$58,483
Blood Management Technologies88,12081,175
MedSurg net revenues$148,062$139,658

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's plasma — total net revenues?
Haemonetics (HAE) reported plasma — total net revenues of $155.52M in Q2 2026.
How has Haemonetics's plasma — total net revenues changed year-over-year?
Haemonetics's plasma — total net revenues increased by 7.2% year-over-year, from $145.07M to $155.52M.
What is the long-term trend for Haemonetics's plasma — total net revenues?
Over 4 years (2022 to 2026), Haemonetics's plasma — total net revenues has grown at a 11.3% compound annual growth rate (CAGR), from $351.35M to $539.63M.
What does plasma — total net revenues mean?
Represents the total gross revenue generated from the sale of plasma-related products and services, net of returns, allowances, and discounts. This is the top-line figure for the plasma segment and serves as the primary gauge of market share and demand. It reflects the overall scale and commercial success of the company's plasma business operations.

Ask your AI about Haemonetics's plasma — total net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude